USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Sanofi

USPTO PatentsView assignee record — 721 granted patents across 67 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

721
Total patents granted
67
CPC technology areas
17.2
Avg claims per patent
+23%
5-year filing velocity

Portfolio overview

Sanofi has been granted 721 US utility patents between 2015 and 2025, placing Sanofi at rank #612 across all assignees tracked by PlainPatent. This portfolio spans 67 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Sanofi is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 66.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 397 grants, compared with 324 in the 2015–2019 window — a +23% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Sanofi's 17.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 67 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sanofi against peers pursuing similar technology classes.

How does Sanofi compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Sanofi holds 721 patents — placing it at rank #612 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

405060708090 20152016201720182019202020212022202320242025 78
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Sanofi patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 78 10.8%
2016 55 7.6%
2017 65 9.0%
2018 57 7.9%
2019 69 9.6%
2020 58 8.0%
2021 44 6.1%
2022 57 7.9%
2023 81 11.2%
2024 79 11.0%
2025 78 10.8%

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Growing

Where it ranks

Overall rank by patents

#612

Across all tracked assignees

Innovation Score

66.5 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Sanofi hold?
Sanofi holds 721 US granted patents filed between 2015 and 2025, spanning 67 technology areas.
What is Sanofi's Innovation Score?
Sanofi has an Innovation Score of 66.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Sanofi focus on?
Sanofi's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 299 patents. The company has filed patents in 67 CPC subclasses total.
Is Sanofi's patent filing rate increasing or decreasing?
Sanofi's recent filing velocity is +23% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Sanofi's patents?
Sanofi's patents average 17.2 claims each. This falls within the standard range, providing solid legal coverage.
How is the Sanofi patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope